Patents by Inventor David J. Loury

David J. Loury has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PURINONE COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20180037583
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: March 22, 2017
    Publication date: February 8, 2018
    Inventors: Wei Chen, Zhaozhong J. Jia, David J. Loury
  • USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)
    Publication number: 20180036313
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Application
    Filed: September 26, 2017
    Publication date: February 8, 2018
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)
    Publication number: 20180015091
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Application
    Filed: July 26, 2017
    Publication date: January 18, 2018
    Inventors: JOSEPH J. BUGGY, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • Inhibitors of Bruton's tyrosine kinase
    Patent number: 9862722
    Abstract: Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: January 9, 2018
    Assignee: Pharmacyclics LLC
    Inventors: Wei Chen, David J. Loury, Tarak D. Mody, Longcheng Wang
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20170362246
    Abstract: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.
    Type: Application
    Filed: August 31, 2017
    Publication date: December 21, 2017
    Inventors: Joseph J. Buggy, Wei Chen, Lee Honigberg, David J. Loury, Zhengying Pan, Erik J. Verner
  • FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF
    Publication number: 20170333731
    Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
    Type: Application
    Filed: December 21, 2016
    Publication date: November 23, 2017
    Inventors: David J. Loury, Joseph J. Buggy, Tarak D. Mody, Erik J. Verner, Norbert Purro, Sriram Balasubramanian
  • Use of inhibitors of bruton'S tyrosine kinase (BTK)
    Patent number: 9814721
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: November 14, 2017
    Assignee: Pharmacyclics LLC
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • Use of inhibitors of bruton's tyrosine kinase (BTK)
    Patent number: 9801881
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: October 31, 2017
    Assignee: Pharmacyclics LLC
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • Use of inhibitors of bruton's tyrosine kinase (Btk)
    Patent number: 9801883
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: October 31, 2017
    Assignee: Pharmacyclics LLC
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)
    Publication number: 20170266186
    Abstract: Methods are provided for treating a hematologic cancer comprising administering an anticancer agent to a subject identified as having an increased mobilization of a subpopulation of lymphocytes from a malignancy following administration of an irreversible Btk inhibitor. Methods also are provided for identification of subjects for treatment and the analysis of cells mobilized from a hematologic malignancy following administration of an irreversible Btk inhibitor.
    Type: Application
    Filed: December 29, 2016
    Publication date: September 21, 2017
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors
    Publication number: 20170246169
    Abstract: Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.
    Type: Application
    Filed: October 13, 2016
    Publication date: August 31, 2017
    Inventors: Lee Honigberg, Erik J. Verner, Joseph J. Buggy, David J. Loury, Wei Chen
  • Inhibitors of bruton's tyrosine kinase
    Patent number: 9708326
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: July 18, 2017
    Assignee: PHARMACYCLICS LLC
    Inventors: Wei Chen, Shunqi Yan, David J. Loury, Leah Lynn Frye, Jeremy Robert Greenwood, Mee Yoo Shelley, Longcheng Wang
  • Purinone compounds as kinase inhibitors
    Patent number: 9637487
    Abstract: Disclosed herein are compounds of Formula (I) that are useful as inhibitors of Bruton's tyrosine kinase: where R6-R10 are as defined herein. Also disclosed are pharmaceutical compositions that include the compounds. The compounds may be used, for example, to treat autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: May 2, 2017
    Assignee: PHARMACYCLICS LLC
    Inventors: Wei Chen, Zhaozhong J. Jia, David J. Loury
  • Inhibitors of Bruton's tyrosine kinase
    Patent number: 9624224
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: April 18, 2017
    Assignee: PHARMACYCLICS LLC
    Inventors: Wei Chen, Longcheng Wang, Zhaozhong J. Jia, David J. Loury
  • Inhibitors of Bruton's tyrosine kinase
    Patent number: 9580416
    Abstract: Disclosed herein are compounds that inhibit Bruton's tyrosine kinase (Btk) having the structure of Formula (B): Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: February 28, 2017
    Assignee: PHARMACYCLICS LLC
    Inventors: Wei Chen, Longcheng Wang, Shunqi Yan, David J. Loury, Zhaozhong J. Jia, Leah Lynn Frye, Jeremy Robert Greenwood, Mee Yoo Shelley, Gordana Babic Atallah, Riccardo Zanaletti, Maria Pia Catalani, Luca Francesco Raveglia
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20170050970
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: October 19, 2016
    Publication date: February 23, 2017
    Inventors: Wei Chen, Longcheng Wang, Zhaozhong J. Jia, David J. Loury
  • USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)
    Publication number: 20170035762
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Application
    Filed: March 10, 2016
    Publication date: February 9, 2017
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • Pyrazolo[3,4-d]pyrimidine and pyrazolo[2,3-d]pyrimidine compounds as kinase inhibitors
    Patent number: 9546172
    Abstract: Disclosed herein are compounds such as those of Formula (I) that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: January 17, 2017
    Assignee: PHARMACYCLICS LLC
    Inventors: Wei Chen, David J. Loury
  • Pyrrolopyrimidine compounds as kinase inhibitors
    Patent number: 9540385
    Abstract: Disclosed herein are pyrrolo[2,3-d]pyrimidine compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: January 10, 2017
    Assignee: PHARMACYCLICS LLC
    Inventors: Wei Chen, David J. Loury, Longcheng Wang
  • PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20160375026
    Abstract: Disclosed herein are methods of using pyrrolo[2,3-d]pyrimidine Btk inhibitors, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, and inflammatory diseases or conditions.
    Type: Application
    Filed: September 9, 2016
    Publication date: December 29, 2016
    Inventors: Wei Chen, David J. Loury, Longcheng Wang